GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
09/11/2026
NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that in connection with the hiring, [...]
Five Vital Nutrients Bestsellers Earn TESTED by SuppCo Certification Verifying Label Claims
09/11/2026
MIDDLETOWN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Vital Nutrients , a practitioner-founded nutritional supplement company, today announced that five of its dietary supplements have earned TESTED by SuppCo [...]
Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures
09/11/2026
The Board approved plan target s a 25%–30% reduction in annualized operating expenses, compared to annualized 2026 GAAP and non-GAAP operating expenses, once fully implemented, expected by the end of Q 1 202 7 Cost [...]
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
09/11/2026
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable [...]
SodaPeak Launch 2026 Advanced Soda Peak Gummies for Male Vitality and Energy Supplement New Information For Multi-Ingredient And Benefits.
09/11/2026
SodaPeak introduces Soda Peak Gummies in the USA, a multi-ingredient dietary supplement formulated for male vitality and energy wellness, with details on ingredients, product features and usage information. New York, [...]
Park Dental Partners Completes Acquisition of Village Family Dental Support Services Organization, Expands into North Carolina
09/11/2026
MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) (the “Company”), a leading dental resource organization, announced that it completed its acquisition of the Village Family Dental [...]
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
09/11/2026
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in [...]
USARAD, a Nanox Company, Expands Collaboration with AZmed to Integrate FDA-Cleared X-ray AI into Its Teleradiology Workflows
09/11/2026
AZmed's FDA-cleared, clinically validated X-ray AI suite to be integrated into USARAD's workflows through Nanox Marketplace Expansion builds on USARAD's existing use of AZmed AI, from acute trauma to chest X-rays, to [...]
Oncovita Granted Orphan Drug Designation For MVdeltaC in Mesothelioma by the European Commission
09/11/2026
Following FDA orphan drug designation in 2025, the European decision marks a further milestone as Oncovita prepares to initiate clinical development in late 2027 The European Commission granted orphan designation on [...]
Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients
09/11/2026
Single-cell sequencing demonstrates pelareorep’s ability to remodel the tumor microenvironment in a hematological cancer SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics [...]
Boehringer Ingelheim's survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase III SYNCHRONIZE-CVOT trial alongside significant cardiometabolic benefits
09/11/2026
SYNCHRONIZE-CVOT met its primary endpoint demonstrating the safety of survodutide in terms of major adverse cardiovascular events compared with placebo in people with obesity and established cardiovascular disease (CVD [...]
Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 SYNCHRONIZE-CVOT trial with significant cardiometabolic benefits
09/11/2026
Company announcement – No. 55 / 2026 Zealand Pharma announces Boehringer Ingelheim’s survodutide is the first glucagon/GLP-1 dual agonist to demonstrate a favorable cardiovascular safety profile in global Phase 3 [...]
Kraig Labs Ships Spider Silk to Developers Across Global Industries
09/11/2026
A Global Apparel Pilot and Shipment to a Materials Innovator with Aerospace Experience Put Customer Feedback in Focus DENVER, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews )—Kraig Biocraft Laboratories ( OTCQB: KBLB [...]
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
09/11/2026
CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Baylor Genetics to Highlight the Clinical Value of Genomics in Pediatric Care at the 2026 National Society of Genetic Counselors Annual Meeting
09/11/2026
Two new data presentations underscore the diagnostic and clinical utility of genome and exome sequencing for pediatric patients with hearing loss and immunodeficiency HOUSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Baylor [...]
NTG Nordic Transport Group A/S – Launch of medium-term financial targets for 2029-2031
09/11/2026
Company announcement no. 46 – 26 09 November 2026 NTG Nordic Transport Group A/S – Launch of medium-term financial targets for 2029-2031 NTG Nordic Transport Group A/S (“NTG”) today launches medium-term financial [...]
NTG Nordic Transport Group publishes interim report for Q3 2026
09/11/2026
Company announcement no. 47 – 26 09 November 2026 NTG Nordic Transport Group publishes interim report for Q3 2026 The interim report for Q3 2026 is enclosed. In connection with publication of the results for Q3 2026, a [...]
Hinge Bio Shares Encouraging Clinical Data for HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026
09/11/2026
Encouraging safety and pharmacodynamic activity observed with HB2198 in normal healthy volunteers was presented with additional preclinical data at the American College of Rheumatology (ACR) Convergence 2026 REDWOOD [...]
Kyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA Neurology
09/11/2026
Publication reinforces miv-cel's potential to deliver durable clinical benefit with a single dose, enabled by miv-cel's unique construct, and become the first approved therapy in SPS and first approved CAR T-cell [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum